Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement.
about
Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy surveyUpdate on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.Menopause, hormone therapy and diabetes.Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps.Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspectiveHormone therapy use in women veterans accessing veterans health administration care: a national cross-sectional study.Informing women on menopause and hormone therapy: Know The Menopause a multidisciplinary project involving local healthcare systemPostmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study.Rapid Evidence Assessment of the Literature (REAL(©)): streamlining the systematic review process and creating utility for evidence-based health care.Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach.Prescribing of FDA-approved and compounded hormone therapy differs by specialty.Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.Investigation of women with postmenopausal uterine bleeding: clinical practice recommendationsSex hormone therapy and progression of cardiovascular disease in menopausal womenPostmenopausal hormone therapy: risks and benefits.Gender difference in the pathophysiology and treatment of glaucoma.Female-specific factors for IHD: across the reproductive lifespan.Publicly funded practice-oriented clinical trials: of importance for healthcare payers.Evolving cardiovascular care for women: a decade of progress.Diabetes and Menopause.Transdermal estrogens in the changing landscape of hormone replacement therapy.Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all.Manipulating bone disease in inflammatory bowel disease patients.Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women?Of conflicts, conspiracies, red herrings, and black swans.Working smarter not harder: Coupling implementation to de-implementation.Postmenopausal hormone therapy in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): who still uses it?Are we there yet? Closing the gender gap in coronary heart disease recognition, management and outcomes.Prevention of Cardiovascular Disease in Women.Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive
P2860
Q27317641-0F0B3DC3-596E-47BC-BE6F-C558E209CA6AQ28081931-4B2DBCC3-83A2-4912-8939-7C11E3A21FD2Q30239769-AD66B9ED-CFEE-4FD4-A4B9-8F9B6A170B99Q30370912-66520E97-9A45-41CA-A3AE-DD98359616A9Q30841046-C7CA863C-91E0-46D2-8804-D53F5BB23CBFQ33644735-68741737-13A1-4C3B-91DD-71E031BD5FCBQ34147730-BEF96F84-9A6F-48E6-96C6-6806232C7603Q34380530-44D82DD8-9327-4CAB-A82D-0D9F4C11111AQ35040292-876F1168-4850-47AE-A3C9-EE5B8DB7949DQ35083087-C31E79DF-0661-4A00-A6AF-37F013CE2414Q35689433-4CE51495-49FE-41EB-BA58-EFD4CE50BC4DQ35829604-3D80186F-F086-4AEB-B410-854D77D1131CQ36648823-60CBF762-8F0C-4A3C-99F2-DBEDFEF6BF8AQ37265844-8287FAE1-6684-4D5B-BEA9-D1FFCEC748B7Q37416371-5E5586D5-4D07-460B-9D6B-3EDDDB94FCAEQ37632488-97264481-2A9C-4158-960C-85149A89B16DQ37651567-20F99C3F-699B-4B35-B6C8-5BCC2E62EE22Q38082563-F01876E8-4ABA-4B27-9B29-8FB516972F97Q38257023-D4E490AE-FA13-4B60-9565-CF30E6E0FAD9Q38332049-813090DA-A9E6-4AFC-B8A2-3744BA112144Q38376709-0B256C4A-76C9-4B87-972E-BF1BDCBCB29BQ38506237-C56CD736-9DAD-43E6-9A8C-494CBE6B422FQ38734483-12046ABF-57E7-4ECB-B7F1-D3590AE8E9F6Q38765828-1263E874-2429-4E48-AD06-4E35890BF43DQ41856851-F8C22600-ECA9-4D91-9E93-F8ED2AA268B4Q42406589-DCE4F0B8-E86D-4E2E-A600-1F7F40F03642Q44592446-A09B95E9-236A-4ABC-A641-3D2D0FF511A4Q45950632-438B9A7B-7514-45CF-B467-C8DC94047419Q47668522-A07F017D-767A-44FD-9504-6070F869D142Q47842567-6BE31696-BBFC-43D3-9ADE-E07698247B61Q54695477-96192B50-CD48-4093-A919-7B6A6E1222D2Q55227472-13F0268B-ADA6-403C-9F2B-D1DD335ADC7EQ56673117-B80A1C9B-A4DE-430A-B3D6-0BA91371354E
P2860
Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Menopausal hormone therapy for ...... orce recommendation statement.
@en
type
label
Menopausal hormone therapy for ...... orce recommendation statement.
@en
prefLabel
Menopausal hormone therapy for ...... orce recommendation statement.
@en
P1476
Menopausal hormone therapy for ...... orce recommendation statement.
@en
P2093
U.S. Preventive Services Task Force
Virginia A Moyer
P356
10.7326/0003-4819-158-1-201301010-00553
P407
P577
2013-01-01T00:00:00Z